雅各臣科研製藥(02633.HK)擬與建豐設合資開發腸胃科及呼吸系統科藥物
格隆匯10月31日丨雅各臣科研製藥(02633.HK)發佈公告，公司全資附屬公司Smiley Sun Limited與建豐胃仙-U有限公司於2019年10月31日訂立合資公司協議。根據合資公司協議，將註冊成立一間新公司，分別由Smiley及建豐持有50%權益，據此，雙方將開發及開拓雅各臣科研製藥集團及建豐旗下腸胃科及呼吸系統科藥物以及食品╱健康補充品市場。
合資公司的業務將為：分銷及銷售訂約雙方若干產品至新市場，該等產品包括建豐產品及雅各臣科研製藥集團產品；發掘及開發該等產品的有關產品╱產品線拓展；及於全球市場發掘及進行有關供應及分銷非處方藥物以及腸胃科及呼吸系統科類別的食品╱健康補充品業務。尤其是相對於Smiley及建豐而言，合資公司將有權優先收購腸胃科及呼吸系統科藥物以及食品╱健康補充品品牌。
據悉，建豐於1960年代在香港註冊成立，主要從事開發腸胃科及呼吸系統科藥物業務。建豐為胃仙-U的品牌擁有人及於中國、香港及澳門的獨家代理。胃仙-U為備受非處方市場認可的腸胃藥，近60年來於中國、香港及澳門廣受歡迎，廣泛用於幫助消化以及舒緩因消化不良、胃痛、胃灼熱、食慾不振及胸口作悶引起的不適。
自2019年1月起，公司全資製藥附屬公司正美藥品有限公司已成為建豐胃仙-U的合約製造商，該公司的生產廠房已獲國際醫藥品稽查協約組織(PIC/S)的良好製造規範(GMP)認證。呼佳噴霧劑為鼻用噴霧的暢銷品牌。呼佳噴霧劑用於減輕因鼻敏感及╱或鼻道狹窄引致的不適症狀，如因一般感冒病毒、花粉或室內塵埃引致的鼻黏膜紅腫或充血。
公司稱，憑藉建立具備強大商業實力的區域市場平台，加上雅各臣科研製藥集團成功夥伴關係的優秀往績，雅各臣科研製藥集團正處於優越位置，與知名合作伙伴進行戰略合作，通過授權、技術轉讓或產品代理，從亞太區及大中華地區的高增長市場潛力中受惠。建豐長久以來為藥劑業界知名翹楚，故董事會認為成立合資公司不僅會締造訂約方之間的協同效應，亦為雅各臣科研製藥集團於開拓地區市場時，並拓展其腸胃科及呼吸系統科藥物以及食物╱健康補充品組合策略上建立重要一環。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
